Log inSign up
AAOIFI No. 21 screening

Is RXRX halal?

Recursion Pharmaceuticals, Inc.

Not halal

Recursion Pharmaceuticals, Inc. did not pass AAOIFI screening. The failed check is shown below.

Checked: 14 October 2026

Exchange

NASDAQ

Price

3.465

Day

-16.71%

Market cap

$2.06B

Industry

Biotechnology

Sector

Healthcare

What the company does

Recursion Pharmaceuticals is a biotech that discovers drugs with AI and robotic labs (merged with Exscientia in 2024), with oncology and rare-disease candidates in trials. No product; funded by investors and partnership payments from Roche and Sanofi.

What was checked

The AAOIFI standard has four steps: business activity first, then three financial ratios. Fail one and the stock is not halal.

  • Business activity

    No prohibited activity

  • Interest-bearing debt / market cap

    limit 30%

    Interest-bearing debt $14.20M ÷ current market cap $2.06B = 0.7%

    0.7%

    Pass

  • Cash & investments / market cap

    limit 30%

    Cash + interest-bearing securities $545.68M ÷ current market cap $2.06B = 26.5%

    26.5%

    Pass

  • Non-compliant income / total revenue

    limit 5%

    Interest income $22.79M ÷ annual revenue $74.26M (2025) = 30.7%

    30.7%

    Fail

Figures from the company's filings (2026-06-30), USD. Market cap is a 36-month average (the S&P Shariah index approach), so a one-day price move does not flip the verdict.

For information (AAOIFI 3/1 note): cash + receivables are 46.2% of total assets (2026-06-30). AAOIFI recommends tangible assets of at least one third — this figure does not affect the verdict, and other major screeners do not apply it either.

In the lists

In the S&P 500
Not in the S&P 500

Halal stocks in the same industry

The largest halal stocks in Biotechnology — for comparison.

Related articles

Halal is the first question. The second: when to enter?

Our scanner watches 1454 halal stocks around the clock and fires a signal with entry, TP and SL when a technical setup completes. The full signal history — with outcomes — is public.

This is neither investment advice nor a fatwa. Screening is based on public financial statements and AAOIFI standard No. 21; data may lag. For a personal decision consult your own scholar.

Earnings historyRXRX's next report date, EPS estimate vs actual for recent quarters and the post-earnings price move.View earnings →